| MARUHO |
MARUHO |
90%
|
The Company concluded that Maruho is a customer under the Maruho Agreement, and as such, the Maruho Agreement falls within the scope of ASC 606 |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from UPB graph: liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biologica… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. In addition, we may incur substantial cost… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
llaboration arrangements with third parties. Until we can generate sufficient product revenue to finance our cash requirements, if ever, we expect to fund our operations through equity offerings or d… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from UPB graph: llaboration arrangements with third parties. Until we can generate sufficient product revenue to finance our cash requ… |
| SNYNF |
Sanofi |
72%
|
or development of AI technologies. In addition, various federal regulators have issued guidance and focused enforcement efforts on the use of AI in regulated sectors. The FDA, for example, issued dra… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from UPB graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from UPB graph: or development of AI technologies. … |
| ASTELLAS-PHARMA-INC |
ASTELLAS-PHARMA-INC |
62%
|
ntinue to incur significant financial losses for the foreseeable future. We are a clinical-stage biopharmaceutical company with a limited operating history. We were formed in April 2021 and our opera… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
Even if we are successful in defending against such claims, litigation could result in substantial costs and distract our technical and management personnel from their normal responsibilities. In add… |
| HONG-KONG-LIMITED |
HONG-KONG-LIMITED |
62%
|
could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; • collaborators may infringe the intellectual property rights of third partie… |
| KONG-LIMITED |
KONG-LIMITED |
62%
|
g Kong) Limited to manufacture the Compound, requiring us to pay a mid-six-figure annual fee to Lonza pursuant to this provision. Any royalties due under the Lonza License Agreement are payable on a … |
| LEERINK-PARTNERS-LLC |
LEERINK-PARTNERS-LLC |
62%
|
rch 31, 2025. The increase of $1.3 million was primarily driven by an increase in personnel expenses of $0.7 million due to increased headcount in our general and administrative functions. Personnel … |
| LONZA-SALES-AG |
LONZA-SALES-AG |
62%
|
llaboration arrangements with third parties. Until we can generate sufficient product revenue to finance our cash requirements, if ever, we expect to fund our operations through equity offerings or d… |
| MARUHO-CO-LTD |
MARUHO-CO-LTD |
62%
|
e continue to make investments to improve the protection of data and information technology, including in the hiring of information technology (“IT”) personnel, periodic cyber security awareness trai… |
| PLAB |
Photronics, Inc. |
62%
|
Reciprocal relationship from PLAB graph: Reciprocal relationship from UPB graph: liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biologica… |
| PROMETHEUS-LABORATORIES-INC |
PROMETHEUS-LABORATORIES-INC |
62%
|
liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. In addition, we may incur substantial cost… |
| REGENERON-PHARMACEUTICALS-INC |
REGENERON-PHARMACEUTICALS-INC |
62%
|
ntinue to incur significant financial losses for the foreseeable future. We are a clinical-stage biopharmaceutical company with a limited operating history. We were formed in April 2021 and our opera… |
